Pfizer Completes £2.5 Billion Sale of Remaining Stake in Haleon

Haleon repurchases shares as part of its buyback program, while BlackRock becomes its largest shareholder.

Pfizer has sold its remaining stake in Haleon for approximately £2.5 billion, marking its full exit from the company.
Haleon repurchased 44 million shares from Pfizer for £3.85 per share, totaling around £170 million.
The remaining 618 million shares were sold to institutional investors, with BlackRock Investment Management emerging as Haleon’s largest shareholder, holding over 5%.
This transaction is part of Haleon’s £500 million share buyback program announced in February 2025, aligning with its capital allocation priorities.
Haleon CEO Brian McNamara described the deal as a significant milestone, emphasizing the company’s strong position and future growth opportunities.